Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 11:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 6,983 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Carcinoma of the Breast Clear all
Terminated Phase 2 Interventional Results available

Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer

NCT00118053
View directory record Official record
Conditions
Breast Cancer
Interventions
herceptin, carboplatin, docetaxel, conventional surgery, radiation therapy
Biological · Drug · Procedure
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
9
States / cities
East Brunswick, New Jersey • Freehold, New Jersey • Hamilton, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Oct 16, 2026, 11:02 AM EDT
Recruiting Phase 1 Interventional

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

NCT07454642
View directory record Official record
Conditions
Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Small Cell Carcinoma of Lung, Colorectal Cancer, Hormone Receptor Positive Breast Carcinoma
Interventions
AVA6103
Drug
Lead sponsor
Avacta Life Sciences Ltd
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Scottsdale, Arizona • Sarasota, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 16, 2026, 11:02 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer

NCT02788981
View directory record Official record
Conditions
Breast Cancer
Interventions
Mifepristone, Placebo, Nab-Paclitaxel
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
5
States / cities
Birmingham, Alabama • Chicago, Illinois • Evanston, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 16, 2026, 11:02 AM EDT
Terminated Phase 4 Interventional Results available

L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer

NCT00754767
View directory record Official record
Conditions
Breast Cancer, Chemotherapeutic Agent Toxicity, Neurotoxicity
Interventions
L-carnitine L-tartrate, placebo
Drug · Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Louis Park, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 16, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue

NCT00792077
View directory record Official record
Conditions
Leukemia, CLL
Interventions
Lenalidomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Oct 16, 2026, 11:02 AM EDT
Terminated Phase 1 Interventional

Rosuvastatin in Treating Women With Cardiovascular Complications Who Are Undergoing Chemotherapy For Breast Cancer

NCT01051401
View directory record Official record
Conditions
Cardiovascular Complications, Recurrent Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
rosuvastatin, placebo, survey administration, management of therapy complications
Drug · Other · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 16, 2026, 11:02 AM EDT
Not yet recruiting Not applicable Interventional

Implementing a Digital Alcohol Intervention to Raise Women's Awareness of Alcohol-related Breast Cancer Risk During Routine Screening Visits

NCT07799467
View directory record Official record
Conditions
Breast Cancer, Alcohol Drinking
Interventions
Sobriety Digital Intervention
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
40 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 16, 2026, 11:02 AM EDT
Terminated Phase 2 Interventional Results available

Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer

NCT00194792
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
exemestane, triptorelin pamoate, capecitabine, methotrexate, vinorelbine tartrate, paclitaxel, therapeutic conventional surgery, radiation therapy, laboratory biomarker analysis
Drug · Procedure · Radiation + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 16, 2026, 11:02 AM EDT
Terminated Phase 4 Interventional Results available

Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors

NCT06162663
View directory record Official record
Conditions
Breast Cancer, Insomnia
Interventions
Suvorexant Tablets, Placebo Control
Drug · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 16, 2026, 11:02 AM EDT
Terminated Phase 1Phase 2 Interventional

Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer

NCT03983395
View directory record Official record
Conditions
Breast Cancer
Interventions
ISB 1302 250 ng/kg, ISB 1302 325 ng/kg, ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22, ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22, ISB 1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22, ISB 1302 325ng/kg D1;550 ng/kg D8;900 ng/kg D15,22, ISB 1302 escalating doses,1200 ng/kg D15,22, ISB 1302 at the MTD and/or RP2D dose
Biological
Lead sponsor
Ichnos Sciences SA
Industry
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
5
States / cities
Gilbert, Arizona • Los Angeles, California • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 16, 2026, 11:02 AM EDT
Completed Phase 1 Interventional

A Study of ZN-c5 in Participants With Breast Cancer

NCT04176757
View directory record Official record
Conditions
Breast Cancer
Interventions
ZN-c5
Drug
Lead sponsor
Zeno Alpha Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Tucson, Arizona • New York, New York • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 16, 2026, 11:02 AM EDT
Active, not recruiting No phase listed Observational

Brain Functional MRI in Older Women With Breast Cancer (Brain fMRI-BC)

NCT01992432
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
City of Hope Medical Center
Other
Eligibility
65 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
2
States / cities
Duarte, California • South Pasadena, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 16, 2026, 11:02 AM EDT
Terminated Phase 2 Interventional

PTK and Letrozole in Post-menopausal Women With Advanced Breast Cancer

NCT00263198
View directory record Official record
Conditions
Breast Neoplasms
Interventions
PTK787/ZK222584, Letrozole
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 7, 2013 · Synced Oct 16, 2026, 11:02 AM EDT
Terminated No phase listed Observational

Monitoring of Neoadjuvant Therapy in Locally-Advanced Breast Cancer

NCT01837563
View directory record Official record
Conditions
Locally Advanced Breast Cancer
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Oct 16, 2026, 11:02 AM EDT
Completed Phase 1 Interventional

Ketogenic Diet and Chemotherapy in Affecting Recurrence in Patients With Stage IV Breast Cancer

NCT03535701
View directory record Official record
Conditions
Stage IV Breast Cancer AJCC v6 and v7
Interventions
Dietary Intervention, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
Dietary Supplement · Other · Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 16, 2026, 11:02 AM EDT
Recruiting Phase 1 Interventional

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

NCT07222267
View directory record Official record
Conditions
Breast Cancer, Advanced Solid Tumor
Interventions
BG-75202, CDK4 Inhibitor, Estrogen Receptor Antagonist, Aromatase Inhibitor
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
6
States / cities
Birmingham, Alabama • New Haven, Connecticut • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 16, 2026, 11:02 AM EDT
Recruiting Not applicable Interventional

Inspiratory Muscle Training for Breast Cancer Patients on Chemotherapy

NCT07386444
View directory record Official record
Conditions
Early Stage Breast Carcinoma, Dyspnea
Interventions
Inspiratory muscle training
Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 16, 2026, 11:02 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones

NCT04090398
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Electronic Health Record Review, Magnetic Resonance Imaging, Paclitaxel, Radium Ra 223 Dichloride, Single Photon Emission Computed Tomography
Procedure · Other · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
30
States / cities
Birmingham, Alabama • Duarte, California • Orange, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 16, 2026, 11:02 AM EDT
Recruiting Not applicable Interventional

The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema

NCT05890677
View directory record Official record
Conditions
Lymphedema, Breast Cancer
Interventions
Surgical Intervention, Conservative Complex Physical Decongestion Therapy
Procedure
Lead sponsor
University Hospital, Basel, Switzerland
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
4
States / cities
New Haven, Connecticut • Boston, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 16, 2026, 11:02 AM EDT
Active, not recruiting Phase 3 Interventional

Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer

NCT05705401
View directory record Official record
Conditions
HER2-positive Breast Cancer
Interventions
Standard of Care Adjuvant Breast Radiation, Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation
Radiation · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
40 Years and older
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2037
U.S. locations
413
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 286 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 16, 2026, 11:02 AM EDT
Terminated Not applicable Interventional

The CEASE Study: Computer Based Educational Module for the Reduction of Arthralgia Syndrome Associated With Endocrine Therapy for Breast Cancer

NCT01351844
View directory record Official record
Conditions
Breast Cancer, Arthralgia
Interventions
Education and exercise intervention, Education and General Exercise
Behavioral
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 16, 2026, 11:02 AM EDT
Completed Phase 1 Interventional

Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

NCT02635672
View directory record Official record
Conditions
Neoplasms
Interventions
VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda, VIP152 (BAY 1251152) 15 mg
Drug
Lead sponsor
Vincerx Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
13
States / cities
Springdale, Arkansas • Louisville, Kentucky • Silver Spring, Maryland + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 16, 2026, 11:02 AM EDT
Completed Phase 1 Interventional

Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1

NCT01234012
View directory record Official record
Conditions
Solid Tumor
Interventions
IMF-001
Biological
Lead sponsor
ImmunoFrontier, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Buffalo, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Oct 16, 2026, 11:02 AM EDT
Completed Not applicable Interventional

Yoga for Symptoms of Nerve Damage Caused by Chemotherapy

NCT03292328
View directory record Official record
Conditions
Breast Cancer, Peripheral Neuropathy, Gynecologic Cancer
Interventions
Yoga, Wait List Control
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 16, 2026, 11:02 AM EDT